Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.

Clinical medicine & research - 1 Nov 2005

Wilke Russell A, Berg Richard L, Vidaillet Humberto J, Caldwell Michael D, Burmester James K, Hillman Michael A

Abstract excerpt

OBJECTIVES: To characterize the impact of several important clinical variables on the rate of anticoagulation during warfarin initiation (i.e., the first 30 days). DESIGN: Retrospective study. SETTING: An anticoagulation service of a large horizontally integrated, multispecialty group practice in central and northern Wisconsin. PARTICIPANTS: Patients with sufficient laboratory data obtained during the initiation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C9

Share to Pharmacogenetics

Share to Prothrombin Time

Share to Time Factors

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 16303885
DOI: 10.3121/cmr.3.4.207
PMCID: PMC1288405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.PMID 16303885Read ↗

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.Semantic proximity Read ↗

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.Semantic proximity Read ↗

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.Semantic proximity Read ↗

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Semantic proximity Read ↗

Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon.Semantic proximity Read ↗

Factors affecting time to maintenance dose in patients initiating warfarin.Semantic proximity Read ↗

Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.Semantic proximity Read ↗

Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.Semantic proximity Read ↗

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.Semantic proximity Read ↗

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.